CEFEPIME VERSUS CEFOTAXIME IN THE TREATMENT OF LOWER RESPIRATORY-TRACT INFECTIONS

被引:19
作者
BARCKOW, D
SCHWIGON, CD
机构
[1] Universitätsklinikum Rudolf- Virchow, Standort Charlottenburg, Berlin, 1000
关键词
D O I
10.1093/jac/32.suppl_B.187
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Patients with lower respiratory tract infection (LRTI) were randomized 2 1 to receive either cefepime 2 g iv bd or cefotaxime 2 g iv tds. Bronchopneumonia alone or associated with another LRTI was diagnosed in 30 of 37 cefepime recipients and in 11 of 18 cefotaxime recipients; other diagnoses included bronchitis, lobar pneumonia and aspiration pneumonia. The mean duration of treatment was 5.9 days in the cefepime group and 5.4 days in the cefotaxime group. There were no significant differences between the two groups with regard to clinical or bacteriological outcome. Treatment was associated with a satisfactory clinical response in 27 (73%) of 37 evaluable cefepime patients and in 10 (56%) of 18 evaluable cefotaxime patients. Treatment resulted in eradication of 33 (89%) of 37 pathogens in the cefepime group, including 13 of 15 strains of Staphylococcus aureus, and of 16 (73%) of 22 pathogens in the cefotaxime group, including eight of ten strains of S. aureus. Two Pseudomonas aerugmosa strains persisted in the cefotaxime group. The sole clinical adverse event reported was a rash in one cefepime patient which did not require discontinuation of treatment. No clinically relevant changes in laboratory test results were attributed to either agent. Cefepime twice daily and cefotaxime three times daily were of comparable safety and efficacy in the treatment of bronchopneumonia and other LRTIs. © 1993 The British Society for Antimicrobial Chemotheraphy.
引用
收藏
页码:187 / 193
页数:7
相关论文
共 8 条
  • [1] INVITRO ACTIVITY OF CEFEPIME, A NEW PARENTERAL CEPHALOSPORIN, AGAINST RECENT EUROPEAN BLOOD ISOLATES AND IN COMPARISON WITH PIPERACILLIN TAZOBACTAM
    DORNBUSCH, K
    MORTSELL, E
    GORANSSON, E
    [J]. CHEMOTHERAPY, 1990, 36 (04) : 259 - 267
  • [2] NEW AND EMERGING ETIOLOGIES FOR COMMUNITY-ACQUIRED PNEUMONIA WITH IMPLICATIONS FOR THERAPY - A PROSPECTIVE MULTICENTER STUDY OF 359 CASES
    FANG, GD
    FINE, M
    ORLOFF, J
    ARISUMI, D
    YU, VL
    KAPOOR, W
    GRAYSTON, JT
    WANG, SP
    KOHLER, R
    MUDER, RR
    YEE, YC
    RIHS, JD
    VICKERS, RM
    [J]. MEDICINE, 1990, 69 (05) : 307 - 316
  • [3] ACTIVITY OF CEFEPIME AGAINST CEFTAZIDIME-RESISTANT AND CEFOTAXIME-RESISTANT GRAM-NEGATIVE BACTERIA AND ITS RELATIONSHIP TO BETA-LACTAMASE LEVELS
    FUNGTOMC, J
    DOUGHERTY, TJ
    DEORIO, FJ
    SIMICHJACOBSON, V
    KESSLER, RE
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (04) : 498 - 502
  • [4] JONES RN, 1992, DIAGN MICR INFEC DIS, V15, pS3
  • [5] COMPARISON OF A NEW CEPHALOSPORIN, BMY 28142, WITH OTHER BROAD-SPECTRUM BETA-LACTAM ANTIBIOTICS
    KESSLER, RE
    BIES, M
    BUCK, RE
    CHISHOLM, DR
    PURSIANO, TA
    TSAI, YH
    MISIEK, M
    PRICE, KE
    LEITNER, F
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 27 (02) : 207 - 216
  • [6] MARRIE TJ, 1989, REV INFECT DIS, V11, P586
  • [7] DEVELOPMENT OF RESISTANCE DURING CEFTAZIDIME AND CEFEPIME THERAPY IN A MURINE PERITONITIS MODEL
    PECHERE, JC
    VLADOIANU, IR
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 29 (05) : 563 - 573
  • [8] 1990, M7A2 NCCLS NAT COMM